Full video transcriptClick to expand
Auto-generated transcript of @drmikeisraetel's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00You can kind of expect maybe about three to five pounds of muscle in the course of roughly 12 weeks of using MK6-7 zone.
- 0:08If you are a well-trained lifter and you push protein into quite high and you are training hard,
- 0:14three to five pounds of muscle, of which you might keep after you come off of this thing and sound like a lot.
- 0:20But three literal pounds of muscle you keep after 12 weeks of going hard for advanced lifters, especially who are older.
- 0:28Man, that's a big deal. That's real take-home.
- 0:31And you can potentially, with moderate to mild impact, very controlled impacts on your health, run two of those cycles a year.
- 0:38Yeah, you know, like an extra four to six pounds a year for a few years is like, I don't know, maybe all the gains you've made in the last few years,
- 0:45it's a big, big deal in the real world.
- 0:47So should you use the Gainesville?
- 0:49No, the sh- is low-key poison.
- 0:50IRL? Can you use it?
- 0:52Yes, knowing your risks and doing your best.
MK-677 as a 'gains pill': what the evidence actually shows
Quick answer
MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that increases endogenous GH and IGF-1 secretion. Human trials have demonstrated lean mass increases primarily in elderly and clinical populations, with documented adverse effects including insulin resistance, edema, and increased fasting glucose. It is not FDA-approved for any indication and carries unresolved long-term safety questions, particularly regarding sustained IGF-1 elevation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 as a 'gains pill': what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 as a 'gains pill': what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "MK-677 as a 'gains pill': what the evidence actually shows" from Mike Israetel. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that increases endogenous GH and IGF-1 secretion.
The reason this review is not generic is the source wording and the canonical claim label "peptides it s a big deal should you use the gains pill mk 677 know yo." In this clip, the useful excerpt is: "You can kind of expect maybe about three to five pounds of muscle in the course of roughly 12 weeks of using MK6-7 zone." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that increases endogenous GH and IGF-1 secretion.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 (ibutamoren) is an orally active ghrelin receptor agonist that increases endogenous GH and IGF-1 secretion. Human trials have demonstrated lean mass increases primarily in elderly and clinical populations, with documented adverse effects including insulin resistance, edema, and increased fasting glucose. It is not FDA-approved for any indication and carries unresolved long-term safety questions, particularly regarding sustained IGF-1 elevation.
- MK-677 is not FDA-approved for any use and has been on the WADA prohibited list since 2008, meaning competitive athletes face disqualification risk.
- The best human evidence for MK-677 lean mass gains comes from elderly and hip fracture populations (Nass et al., 2008), not trained athletes, so the 3-5 lb figure for gym-goers is an extrapolation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- MK-677 is not FDA-approved for any use and has been on the WADA prohibited list since 2008, meaning competitive athletes face disqualification risk.
- The best human evidence for MK-677 lean mass gains comes from elderly and hip fracture populations (Nass et al., 2008), not trained athletes, so the 3-5 lb figure for gym-goers is an extrapolation.
- Murphy et al. (1998, JCEM) found measurable increases in fasting glucose and reduced insulin sensitivity in MK-677 users, which is a real metabolic concern, not a minor side note.
- Lean body mass gains in studies include water and glycogen retention, meaning actual contractile muscle accrual is likely lower than total lean mass numbers suggest.
- Chronic elevation of IGF-1 carries theoretical long-term risks including acceleration of pre-existing neoplasms, though causation at these doses has not been established in controlled human trials.
- Anyone using or considering MK-677 should have baseline fasting glucose, HbA1c, and IGF-1 levels tested before starting and monitored during use, under direct physician supervision.
- The creator's own 'low-key poison' framing is closer to an honest risk summary than the 'moderate to mild impact' language used later in the same clip.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drmikeisraetel actually say?
Dr. Mike Israetel claims that MK-677 can produce "three to five pounds of muscle" over 12 weeks, that you might keep some of that after stopping, and that running two cycles per year could mean "an extra four to six pounds a year." He also made an unusually candid admission: he called it "low-key poison" before pivoting to a pragmatic "knowing your risks" framing. That tension between "here are the gains" and "this stuff is risky" is the whole ballgame here, and it deserves unpacking rather than a simple thumbs up or down.
To his credit, he did not tell viewers to use it. He framed it as a personal risk calculation. That is a more honest approach than most MK-677 content on this platform, which tends to skip the poison part entirely.
Does the science back this up?
The 3-5 pound muscle gain figure is in the right neighborhood but requires serious caveats about what the studies actually measured and who the subjects were. Most MK-677 trials are not 12-week hypertrophy studies in resistance-trained athletes.
The most-cited human trial (Svensson et al., 1998, Journal of Clinical Endocrinology and Metabolism) found increases in lean body mass in healthy older adults, but lean body mass is not the same as muscle. It includes water and glycogen. A later study by Nass et al. (2008, Annals of Internal Medicine) in older adults with hip fractures showed improved lean mass and function, but again, not a gym population. The data in well-trained younger lifters is essentially nonexistent in peer-reviewed literature. Israetel is extrapolating from clinical and elderly populations to advanced athletes, which is a significant leap. The gains may be real, but the exact numbers are not established for his stated audience.
What did they get wrong (or right)?
He got the general mechanism right. MK-677 is a ghrelin mimetic that stimulates growth hormone secretion, and yes, elevated GH and IGF-1 can support muscle protein synthesis. That part is not controversial.
Where it gets shakier: the framing that health impacts are "very controlled" and "moderate to mild" is doing a lot of heavy lifting. MK-677 is associated with increased fasting glucose and insulin resistance (Murphy et al., 1998, Journal of Clinical Endocrinology and Metabolism), water retention, and in some users significant edema. There is also a documented increase in appetite that can be substantial. For people with pre-diabetes, insulin sensitivity issues, or cardiovascular risk factors, "mild impact" is not the right description. The "low-key poison" quip lands closer to the truth than the "moderate impact" framing does.
He also did not mention that MK-677 is not approved by the FDA for any indication, is not a peptide in the strict pharmacological sense but a small molecule, and has been banned by WADA since 2008.
What should you actually know?
MK-677 sits in a genuinely complicated space. It is not a synthetic anabolic steroid, but it is not a harmless supplement either. The honest version of the risk profile looks like this: chronic elevation of GH and IGF-1 carries theoretical long-term risks including promotion of existing neoplasms, though causation in humans at these doses is not established. Short-term, the metabolic side effects are real and measurable.
If you are considering MK-677 through any channel, including a telehealth platform, the conversation should start with baseline bloodwork covering fasting glucose, HbA1c, and IGF-1 levels, and those markers should be tracked during use. Anyone with a personal or family history of cancer, diabetes, or acromegaly-related conditions should approach this with significant caution and direct physician involvement, not a TikTok comment section.
The gains Israetel describes are plausible but not proven in the specific population he is addressing. The risks he briefly names are real and in some cases underplayed.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Mike Israetel · TikTok creator
137.3K views on this video
It's a BIG DEAL. Should you use the gains pill??? MK-677 KNOW YOUR RISKS - Watch the full video on the @rpstrength YouTube
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about mk-677?
MK-677 is not FDA-approved for any use and has been on the WADA prohibited list since 2008, meaning competitive athletes face disqualification risk.
What does the video say about the best human evidence for mk-677 lean mass gains comes?
The best human evidence for MK-677 lean mass gains comes from elderly and hip fracture populations (Nass et al., 2008), not trained athletes, so the 3-5 lb figure for gym-goers is an extrapolation.
What does the video say about murphy et al. (1998, jcem) found measurable increases in fasting?
Murphy et al. (1998, JCEM) found measurable increases in fasting glucose and reduced insulin sensitivity in MK-677 users, which is a real metabolic concern, not a minor side note.
What does the video say about lean body mass gains in studies include water?
Lean body mass gains in studies include water and glycogen retention, meaning actual contractile muscle accrual is likely lower than total lean mass numbers suggest.
What does the video say about chronic elevation of igf-1 carries theoretical long-term risks including acceleration?
Chronic elevation of IGF-1 carries theoretical long-term risks including acceleration of pre-existing neoplasms, though causation at these doses has not been established in controlled human trials.
What does the video say about anyone using?
Anyone using or considering MK-677 should have baseline fasting glucose, HbA1c, and IGF-1 levels tested before starting and monitored during use, under direct physician supervision.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Mike Israetel, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.